Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 249

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Smith, Matthew, De Bono, Johann, Sternberg, Cora, Le Moulec, Sylvestre, Oudard, Stéphane, De Giorgi, Ugo, Krainer, Michael, Bergman, Andries, Hoelzer, Wolfgang, De Wit, Ronald, Bögemann, Martin, Saad, Fred, Cruciani, Giorgio, Thiery-Vuillemin, Antoine, Feyerabend, Susan, Miller, Kurt, Houédé, Nadine, Hussain, Syed, Lam, Elaine, Polikoff, Jonathan, Stenzl, Arnulf, Mainwaring, Paul, Ramies, David, Hessel, Colin, Weitzman, Aaron, Fizazi, Karim·2016·Journal of Clinical Oncology

Abstract

Purpose: Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, and has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib with prednisone in patients with mCRPC. Patients and Methods: Men with progressive mCRPC after docetaxel and abiraterone and/or enzalutamide were randomly assigned at a two-to-one ratio to cabozantinib 60 mg once per day or prednisone 5 mg twice per day. The primary end point was overall survival (OS). Bone scan response (BSR) at week 12 as assessed by independent review committee was the secondary end point; radiographic progression-free survival (rPFS) and effects on circulating tumor cells (CTCs), bone biomarkers, serum prostate-specific antigen (PSA), and symptomatic skeletal events (SSEs) were exploratory assessments. Results: A total of 1,028 patients were randomly assigned to cabozantinib (n = 682) or prednisone (n = 346). Median OS was 11.0 months with cabozantinib and 9.8 months with prednisone (hazard ratio, 0.90; 95% CI, 0.76 to 1.06; stratified log-rank P = .213). BSR at week 12 favored cabozantinib (42% v 3%; stratified Cochran-Mantel-Haenszel P < .001). rPFS was improved in the cabozantinib group (median, 5.6 v 2.8 months; hazard ratio, 0.48; 95% CI, 0.40 to 0.57; stratified log-rank P < .001). Cabozantinib was associated with improvements in CTC conversion, bone biomarkers, and post–random assignment incidence of SSEs but not PSA outcomes. Grade 3 to 4 adverse events and discontinuations because of adverse events were higher with cabozantinib than with prednisone (71% v 56% and 33% v 12%, respectively). Conclusion: Cabozantinib did not significantly improve OS compared with prednisone in heavily treated patients with mCRPC and progressive disease after docetaxel and abiraterone and/or enzalutamide. Cabozantinib had some activity in improving BSR, rPFS, SSEs, CTC conversions, and bone biomarkers but not PSA outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.65.5597

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 249

Metadata

Authors
Smith, M., De Bono, J., Sternberg, C., Le Moulec, S., Oudard, S., De Giorgi, U., Krainer, M., Bergman, A., Hoelzer, W., De Wit, R., Bögemann, M., Saad, F., Cruciani, G., Thiery-Vuillemin, A., Feyerabend, S., Miller, K., Houédé, N., Hussain, S., Lam, E., Polikoff, J., Stenzl, A., Mainwaring, P., Ramies, D., Hessel, C., Weitzman, A., & Fizazi, K.
Venue
Journal of Clinical Oncology
Published
2016-09-01
Volume
34
Issue
25
Pages
3005-3013
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2471050799
Cited by
249
References
8
FWCI
30.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. https://app.cochat.ai/papers/10.1200/jco.2015.65.5597
The paper
Smith, M., De Bono, J., Sternberg, C., Le Moulec, S., Oudard, S., De Giorgi, U., Krainer, M., Bergman, A., Hoelzer, W., De Wit, R., Bögemann, M., Saad, F., Cruciani, G., Thiery-Vuillemin, A., Feyerabend, S., Miller, K., Houédé, N., Hussain, S., Lam, E., . . . Fizazi, K. (2016). Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.65.5597

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.